ALXP
ALERS
Market cap301mUSD
Oct 28, Last price
26.40EUR
1D
0.00%
1Q
22.79%
Jan 2017
325.81%
IPO
-73.49%
Name
Eurobio Scientific SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The company's portfolio features the Tetanus Quick Stick, an essential emergency diagnostic for rapidly determining a patient's tetanus vaccination status. It also distributes cell culture media, molecular biology reagents, and proprietary antibody solutions. Proprietary developments from Eurobio Scientific encompass the BJI InoPlex, a multiplex serological test for diagnosing prosthetic joint infections, and the EBX-044 PCR test, utilized for identifying SARS-CoV-2 variants. Its licensed offerings include AlloMap, a gene-expression profiling blood test designed for the ongoing surveillance of heart transplant recipients. The firm, initially named Diaxonhit, changed its corporate identity to Eurobio Scientific S.A. in June 2018. Founded in 1997, the company is headquartered in Les Ulis, France.
Key people
Laurent Condomine
Chairman of the Supervisory Board · since 2004
Jean-Pierre Hermet
Vice Chairman of the Supervisory Board · since 2013
Patrick J Langlois
Vice Chairman of the Supervisory Board · since 2008
Loic Maurel
Chairman of the Management Board, Director of Operations and Member of the Executive Committee · since 2012
Thomas Iff
Chief Business Officer
Jacques Martin
Member of the Executive Committee and Vice President Marketing · since 2012
Member of the Supervisory Board · since 2006
Herve Duchesne de Lamotte
Chief Financial and Administrative Officer, Member of the Management Board and Member of the Executive Committee · since 2012
IPO date
Nov 18, 2005
Employees
286
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
7 AVENUE DE SCANDINAVIE
ZA DE COURTABOEUF
LES ULIS 91940
FR
ZA DE COURTABOEUF
LES ULIS 91940
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT | |